Related Experiment Video

Updated: Aug 7, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Lung adenocarcinoma harboring mutations in the ERBB2 kinase domain

Makoto Sonobe1, Toshiaki Manabe, Hiromi Wada

  • 1Department of Thoracic Surgery, Kyoto University Hospital, Kyoto 606-8507, Japan.

The Journal of Molecular Diagnostics : JMD
|July 11, 2006
PubMed

Insights

ERBB2 gene mutations were found in 1.8% of non-small cell lung cancer (NSCLC) patients, specifically in adenocarcinomas. These mutations were observed in nonsmokers and linked to distinct pathological features.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Mutations in the ERBB2 kinase domain are implicated in non-small cell lung cancer (NSCLC).
  • Understanding ERBB2 mutations is crucial for targeted therapies in lung cancer.

Purpose of the Study:

  • To investigate the frequency and characteristics of ERBB2 gene mutations in NSCLC patients.
  • To correlate ERBB2 mutations with clinical and pathological features of NSCLC.

Main Methods:

  • Analysis of tumor specimens from 223 NSCLC patients undergoing resection.
  • Screening for mutations in exons 19 and 20 of the ERBB2 gene.
  • Correlation of mutation status with patient clinical data and tumor pathology.

Main Results:

  • ERBB2 mutations were identified in 1.8% (4/223) of NSCLC tumors.
  • All identified mutations were in-frame insertions within exon 20.
  • Mutated tumors were exclusively adenocarcinomas and occurred in nonsmoking patients.
  • Pathological subtypes included papillary and mixed patterns; no bronchio-alveolar component was observed.

Conclusions:

  • ERBB2 mutations in NSCLC appear in a subset of patients, predominantly nonsmokers with adenocarcinoma.
  • These mutations share some clinical similarities with EGFR mutations but have distinct pathological features.
  • Further research into ERBB2-mutated NSCLC may reveal new therapeutic strategies.

More Related Videos

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...